Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction.

Ando R, Ueda S, Yamagishi S, Miyazaki H, Kaida Y, Kaifu K, Yokoro M, Nakayama Y, Obara N, Fukami K, Takeuchi M, Okuda S.

Diab Vasc Dis Res. 2013 Sep;10(5):436-41. doi: 10.1177/1479164113486662. Epub 2013 Jun 13.

PMID:
23766377
3.

Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level.

Ishibashi Y, Yamagishi S, Matsui T, Ohta K, Tanoue R, Takeuchi M, Ueda S, Nakamura K, Okuda S.

Metabolism. 2012 Aug;61(8):1067-72. doi: 10.1016/j.metabol.2012.01.006. Epub 2012 Mar 3.

PMID:
22386936
4.

Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.

Ojima A, Ishibashi Y, Matsui T, Maeda S, Nishino Y, Takeuchi M, Fukami K, Yamagishi S.

Am J Pathol. 2013 Jan;182(1):132-41. doi: 10.1016/j.ajpath.2012.09.016. Epub 2012 Nov 14.

PMID:
23159951
5.

Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice.

Desai A, Zhao Y, Warren JS.

Nephrol Dial Transplant. 2008 May;23(5):1513-20. doi: 10.1093/ndt/gfm869. Epub 2008 Jan 19.

6.

Involvement of the endothelial DDAH/ADMA pathway in nitroglycerin tolerance: the role of ALDH-2.

Zhang GG, Shi RZ, Jiang DJ, Chen YR, Jia-Chen, Tang ZY, Bai YP, Xiao HB, Li YJ.

Life Sci. 2008 Mar 26;82(13-14):699-707. doi: 10.1016/j.lfs.2008.01.002. Epub 2008 Jan 18.

PMID:
18289604
7.

Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase.

Scalera F, Kielstein JT, Martens-Lobenhoffer J, Postel SC, Täger M, Bode-Böger SM.

J Am Soc Nephrol. 2005 Apr;16(4):892-8. Epub 2005 Feb 23.

8.

Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway.

Tan B, Jiang DJ, Huang H, Jia SJ, Jiang JL, Hu CP, Li YJ.

Vascul Pharmacol. 2007 May;46(5):338-45. Epub 2007 Jan 19.

PMID:
17293168
9.

Gene transfer of dimethylarginine dimethylaminohydrolase-2 improves the impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells induced by lysophosphatidylcholine.

Feng M, Liu L, Guo Z, Xiong Y.

Eur J Pharmacol. 2008 Apr 14;584(1):49-56. doi: 10.1016/j.ejphar.2008.01.029. Epub 2008 Feb 5.

PMID:
18342305
10.

Nitric oxide upregulates dimethylarginine dimethylaminohydrolase-2 via cyclic GMP induction in endothelial cells.

Sakurada M, Shichiri M, Imamura M, Azuma H, Hirata Y.

Hypertension. 2008 Nov;52(5):903-9. doi: 10.1161/HYPERTENSIONAHA.108.114207. Epub 2008 Sep 29.

11.

Lysophosphatidylcholine-induced elevation of asymmetric dimethylarginine level by the NADPH oxidase pathway in endothelial cells.

Jia SJ, Jiang DJ, Hu CP, Zhang XH, Deng HW, Li YJ.

Vascul Pharmacol. 2006 Mar;44(3):143-8. Epub 2005 Nov 23.

PMID:
16309971
12.

Regulation by DDAH/ADMA pathway of lipopolysaccharide-induced tissue factor expression in endothelial cells.

Xin HY, Jiang DJ, Jia SJ, Song K, Wang GP, Li YJ, Chen FP.

Thromb Haemost. 2007 May;97(5):830-8.

PMID:
17479195
13.

Protective effect of neferine on endothelial cell nitric oxide production induced by lysophosphatidylcholine: the role of the DDAH-ADMA pathway.

Peng ZY, Zhang SD, Liu S, He BM.

Can J Physiol Pharmacol. 2011 Apr;89(4):289-94. doi: 10.1139/Y11-021. Epub 2011 Apr 28.

PMID:
21526974
14.

Role of dimethylarginine dimethylaminohydrolases in the regulation of endothelial nitric oxide production.

Pope AJ, Karrupiah K, Kearns PN, Xia Y, Cardounel AJ.

J Biol Chem. 2009 Dec 18;284(51):35338-47. doi: 10.1074/jbc.M109.037036. Epub .

15.

Inhibitory effect of resveratrol derivative BTM-0512 on high glucose-induced cell senescence involves dimethylaminohydrolase/asymmetric dimethylarginine pathway.

Yuan Q, Peng J, Liu SY, Wang CJ, Xiang DX, Xiong XM, Hu CP, Li YJ.

Clin Exp Pharmacol Physiol. 2010 May;37(5-6):630-5. doi: 10.1111/j.1440-1681.2010.05368.x. Epub 2010 Feb 4.

PMID:
20132235
16.

Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications.

Yamagishi S, Ueda S, Nakamura K, Matsui T, Okuda S.

Curr Pharm Des. 2008;14(25):2613-8. Review.

PMID:
18991678
17.

PRMT-1 and DDAHs-induced ADMA upregulation is involved in ROS- and RAS-mediated diabetic retinopathy.

Chen Y, Xu X, Sheng M, Zhang X, Gu Q, Zheng Z.

Exp Eye Res. 2009 Dec;89(6):1028-34. doi: 10.1016/j.exer.2009.09.004. Epub 2009 Sep 11.

PMID:
19748504
18.

Asymmetric dimethylarginine, endothelial dysfunction and renal disease.

Aldámiz-Echevarría L, Andrade F.

Int J Mol Sci. 2012;13(9):11288-311. doi: 10.3390/ijms130911288. Epub 2012 Sep 10. Review.

20.

The role of profilin-1 in endothelial cell injury induced by advanced glycation end products (AGEs).

Li Z, Zhong Q, Yang T, Xie X, Chen M.

Cardiovasc Diabetol. 2013 Oct 4;12:141. doi: 10.1186/1475-2840-12-141.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk